A review of psychedelics trials completed in depression, informed by European regulatory perspectives.

Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P

DOI: 10.1016/j.nsa.2025.105516
Published: 2025
Container: Neuroscience applied
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.nsa.2025.105516,
  title = {A review of psychedelics trials completed in depression, informed by European regulatory perspectives.},
  author = {Silva F and Butlen-Ducuing F and Guizzaro L and Balabanov P},
  year = {2025},
  journal = {Neuroscience applied},
  doi = {10.1016/j.nsa.2025.105516},
  url = {https://doi.org/10.1016/j.nsa.2025.105516}
}

RIS

TY  - JOUR
TI  - A review of psychedelics trials completed in depression, informed by European regulatory perspectives.
AU  - Silva F
AU  - Butlen-Ducuing F
AU  - Guizzaro L
AU  - Balabanov P
PY  - 2025
JO  - Neuroscience applied
DO  - 10.1016/j.nsa.2025.105516
UR  - https://doi.org/10.1016/j.nsa.2025.105516
ER  -

APA

F, S., F, B., L, G., & P, B. (2025). A review of psychedelics trials completed in depression, informed by European regulatory perspectives.. Neuroscience applied. https://doi.org/10.1016/j.nsa.2025.105516

Source records

pubmed · retrieved 2026-09-25T11:51:33.876Z